National Cancer Institute support for targeted alpha-emitter therapy.

Julie A HongMartin BrechbielJeff BuchsbaumChristie A CanariaC Norman ColemanFreddy E EscorciaMichael EspeyCharles KunosFrank LinDeepa NarayananJacek Capala

Published in: European journal of nuclear medicine and molecular imaging (2021)

Given the great potential of RPT, our goal is to continue to encourage its development that will generate the high-quality evidence needed to bring this multidisciplinary treatment to patients.

Keyphrases

end stage renal disease
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
stem cells
cancer therapy
drug delivery
mesenchymal stem cells